Health and economic impact of rotavirus vaccination in GAVI-eligible countries

BMC Public Health

Volumn 10, Issue , 2010, Pages

  Kim, Sun Young ^a,b   Sweet, Steve ^a   Slichter, David ^a,b   Goldie, Sue J ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Harvard Initiative for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; HEALTH CARE COST; HEALTH SURVEY; HUMAN; INFANT; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; ROTAVIRUS INFECTION;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HEALTH EXPENDITURES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; POPULATION SURVEILLANCE; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 77954100931     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-253     Document Type: Article

References (68)

1. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. M Kosek C Bern RL Guerrant, Bull World Health Organ 2003 81 3 197 204 12764516
2. Global illness and deaths caused by rotavirus disease in children. UD Parashar EG Hummelman JS Bresee MA Miller RI Glass, Emerg Infect Dis 2003 9 5 565 72 12737740
3. Global Mortality Associated with Rotavirus Disease among Children in 2004. UD Parashar A Burton C Lanata C Boschi-Pinto K Shibuya D Steele M Birmingham RI Glass, Journal of Infectious Diseases 2009 200 s1 9 S15 10.1086/605025 19817620
4. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. N Santos Y Hoshino, Rev Med Virol 2005 15 29 56 10.1002/rmv.448 15484186
5. Heterogeneity and temporal dynamics of evolution of G1 human rotaviruses in a settled population. S Arista GM Giammanco S De Grazia S Ramirez C Lo Biundo C Colomba A Cascio V Martella, J Virol 2006 80 21 10724 33 10.1128/JVI.00340-06 16928744
6. Sequence analysis of the VP7 gene of human rotavirus G1 isolated in Japan, China, Thailand, and Vietnam in the context of changing distribution of rotavirus G-types. QD Trinh TA Nguyen TG Phan P Khamrin H Yan PL Hoang N Maneekarn Y Li F Yagyu S Okitsu H Ushijima, J Med Virol 2007 79 7 1009 16 10.1002/jmv.20920 17516525
7. Clinical and epidemiological aspects of rotavirus infection. M Zahn GS Marshall, Pediatr Ann 2006 35 1 23 8 16466072
8. Rotavirus Vaccines. WHO, Weekly Epidemiological Record 2007 82 32 285 296 17691162
9. Rotavirus vaccines - an update. PH Dennehy, Vaccine 2007 25 16 3137 41 10.1016/j.vaccine.2007.01.102 17321017
10. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. WHO, Weekly Epidemiological Record 2009 84 23 220 236 19499606
11. Global networks for surveillance of rotavirus gastroenteritis, 2001-2008. WHO, Weekly Epidemiological Record 2008 83 47 421 5 19024780
12. Disease Control Priorities in Developing Countries. 2nd edition DT Jamison JG Breman AR Measham G Alleyne M Claeson DB Evans P Jha A Mills P Musgrove, New York: Oxford University Press 2 2006
13. Making choices in health: WHO guide to cost-effectiveness analysis. T Tan-Torres Edejer R Baltussen T Adam R Hutubessy A Acharya DB Evans CJL Murray, Geneva: World Health Organization 2003
14. Methods for the economic evaluation of health care programmers. MF Drummond MJ Sculpher GW Torrance BJ O'Brian GL Stoddart, New York, NY: Oxford University Press 2005
15. WHO guide for standardization of economic evaluations of immunization programmes. WHO, Geneva: World Health Organization 2008
16. Cost-effectiveness of Rotavirus Vaccination in Vietnam. S Kim SJ Goldie JS Salomon, BMC Public Health 2009 9 29 10.1186/1471-2458-9-29 19159483
17. Exploring Model Uncertainty in Economic Evaluation of Health Interventions. SY Kim SJ Goldie JA Salomon, Society for Medical Decision Making Annual Meeting, Hollywood, CA 2009
18. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. GM Ruiz-Palacios I Perez-Schael FR Velazquez H Abate T Breuer SC Clemens Human Rotavirus Vaccine Study Group,, et al. N Engl J Med 2006 354 1 11 22 10.1056/NEJMoa052434 16394298
19. The Global Burden of Disease, Vol. 1 of Global Burden of Disease and Injury Series. CJL Murray AD Lopez, Cambridge, MA: Harvard University Press 1996
20. Sensitivity an uncertainty analyses for burden of disease and risk factor estimates. CD Mathers JA Salomon M Ezzati S Begg SV Hoorn AD Lopez, Global Burden of Disease and Risk Factors Edited by: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Washington: Oxford University Press 2006 399 426
21. GAVI Alliance, Candidate Rotavirus Vaccine Recommendations for Consideration by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization Geneva 2009
22. WHO, World Health Statistics WHO, Geneva 2008
23. World Population Prospects: The 2006 Revision. Nations United Department of Economic and Social Affairs Division Population, CD-ROM Edition - Extended Dataset in Excel and ASCII formats (United Nations publication, Sales No. E.07.XIII.7) 2007
24. Life tables for WHO member states: 2006. WHO, http://www.who.int/whosis/ database/life-tables/life-tables.cfm
25. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan. ET Flem R Latipov ZS Nurmatov Y Xue KT Kasymbekova RD Rheingans, J Infect Dis 2009 200 Suppl 1 195 202 10.1086/605040 19817600
26. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. RD Rheingans D Constenla L Antil BL Innis T Breuer, Rev Panam Salud Publica 2007 21 4 205 216 17612464 (Pubitemid 47147596)
27. How much could rotavirus vaccines reduce diarrhea-associated mortality in northern Ghana? A model to assess impact. ML Arvay AT Curns S Terp G Armah P Wontuo UD Parashar F Binka RI Glass MA Widdowson, J Infect Dis 2009 200 Suppl 1 85 S91 10.1086/605062 19817619
28. Epidemiology of rotavirus gastroenteritis among children <5 years of age in Morocco during 1 year of sentinel hospital surveillance, June 2006-May 2007. M Benhafid M Youbi JD Klena JR Gentsch N Teleb MA Widdowson, J Infect Dis 2009 200 70 5 10.1086/605048 19817617
29. Estimated rotavirus deaths for children under 5 years of age: 2004. WHO, http://www.who.int/immunization-monitoring/burden/rotavirus-estimates/en/index. html
30. Database on labour statistics (LABORSTA). International Labour Office, http://laborsta.ilo.org/
31. World Development Indicators Online. Bank World, http://web.worldbank. org/WBSITE/EXTERNAL/DATASTATISTICS/0,contentMDK:20398986∼pagePK: 64133150∼piPK:64133175∼theSitePK:239419,00.html
32. Policy Brief: GAVI Alliance New Vaccine Co-financing Policy. GAVI Alliance, Geneva 2009
33. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. AC Linhares FR Velázquez I Pérez-Schael X Sá-Llorens H Abate F Espinoza P López M Macías-Parra E Ortega-Barría DM Rivera-Medina L Rivera N Pavía-Ruz E Nuñez S Damaso GM Ruiz-Palacios B De Vos M O'Ryan P Gillard, Lancet 2008 371 9619 1181 9 10.1016/S0140-6736(08)60524-3 18395579
34. Principles of good practice for budget impact analysis: Report of the ISPOR task force on good research practices-Budget impact analysis. JA Mauskopf SD Sullivan L Annemans J Caro CD Mullins M Nuijten E Orlewska J Watkins P Trueman, Value in Health 2007 10 5 336 47 10.1111/j.1524-4733.2007.00187.x 17888098
35. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. DA Marshall PR Douglas MF Drummond GW Torrance S MacLeod O Manti L Cheruvu R Corvari, Pharmacoeconomics 2008 26 6 477 95 10.2165/00019053-200826060-00003 18489199
36. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. D Atherly R Dreibelbis UD Parashar C Levin J Wecker RD Rheingans, J Infect Dis 2009 200 Suppl 1 28 38 10.1086/605033 19817610
37. Estimating the Costs of Achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. LJ Wolfson F Gasse S Lee-martin P Lydon A Magan A Tibouti B Johns R Hutubessy P Salama JM Okwo-Bele, Bulletin of the World Health Organization 2008 86 1 27 39 10.2471/BLT.07.045096 18235887
38. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. WHO, WHO, Geneva 2002
39. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. J Rose RL Hawthorn B Watts ME Singer, BMJ 2009 339 3653 10.1136/bmj.b3653 19783581
40. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. TK Fischer DD Anh L Antil ND Cat PE Kilgore VD Thiem R Rheingans H Tho le RI Glass JS Bresee, J Infect Dis 2005 192 10 1720 6 10.1086/497339 16235169
41. Projected cost-effectiveness of rotavirus vaccination for children in Asia. LJ Podewils L Antil E Hummelman J Bresee UD Parashar R Rheingans, J Infect Dis 2005 192 Suppl 1 133 45 10.1086/431513 16088797
42. Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine. ET Isakbaeva E Musabaev L Antil R Rheingans R Juraev RI Glass JS Bresee, Vaccine 2007 25 373 380 10.1016/j.vaccine.2006.07.029 16930784
43. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. JE Tate RD Rheingans CE O'Reilly B Obonyo DC Burton JA Tornheim K Adazu P Jaron B Ochieng T Kerin L Calhoun M Hamel K Laserson RF Breiman DR Feikin ED Mintz MA Widdowson, J Infect Dis 2009 200 Suppl 1 76 84 10.1086/605058 19817618
44. Rotavirus gastroenteritis in uzbekistan: implications for vaccine policy in central Asia. ET Flem E Musabaev R Juraev T Kerin J Gentsch RI Glass JS Bresee, J Infect Dis 2009 200 Suppl 1 114 24 19817591
45. Cost-effectiveness of rotavirus vaccination in peru. AD Clark DG Walker NR Mosqueira ME Penny CF Lanata J Fox-Rushby CF Sanderson, J Infect Dis 2009 200 Suppl 1 114 24 10.1086/605043 19817591
46. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. O Ortega N El-Sayed JW Sanders Z Abd-Rabou L Antil J Bresee A Mansour I Adib I Nahkla MS Riddle, J Infect Dis 2009 200 Suppl 1 92 8 10.1086/605057 19817621
47. Potential cost-effectiveness of a rotavirus immunization program in rural China. XY Wang A Riewpaiboon L von Seidlein XB Chen PE Kilgore JC Ma SX Qi ZY Zhang ZY Hao JC Chen ZY Xu, Clin Infect Dis 2009 49 8 1202 10 10.1086/605632 19739973
48. Cost-effectiveness anlisis of routine rotavirus vaccination in Brazil. PC Soarez J Valentim AMC Sartori HMD Novaes, Rev Panam Salud Publica 2008 23 4 221 230 18505602
49. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: The case of Mexico. A Valencia-Mendoza SM Bertozzi JP Gutierrez R Itzler, BMC Infectious Diseases 2008 8 103 10.1186/1471-2334-8-103 18664280
50. Economic Impact of a Rotavirus Vaccine in Brazil. DO Constenla AC Linhares RD Rheingans LR Antil EA Waldman LJ da Silva, J HEALTH POPUL NUTR 2008 26 4 388 396 19069617
51. Economic impact of a rotavirus vaccination program in Mexico. D Constenla FR Velázquez RD Rheingans L Antil Y Cervantes, Rev Panam Salud Publica 2009 25 6 481 90 10.1590/S1020-49892009000600003 19695142
52. Economic Costs of Rotavirus Gastroenteritis and Cost-Effectiveness of Vaccination in Developing Countries. RD Rheingans L Antil R Dreibelbis LJ Podewils JS Bresee UD Parashar, Journal of Infectious Diseases 2009 200 16 27 10.1086/605026 19817595
53. Evaluating rotavirus vaccination in England and Wales: Part II. The potential cost-effectiveness of vaccination. M Jit WJ Edmunds, Vaccine 2007 25 3971 3979 10.1016/j.vaccine.2007.02.070 17400341 (Pubitemid 46616994)
54. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. PK Lorgelly D Joshi M Iturriza Gámara J Gray M Mugford, Epidemiol Infect 2008 136 1 1 12 17553179
55. Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States. MA Widdowson, Pediatrics 2007 119 4 684 697 10.1542/peds.2006- 2876 17403839
56. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. H Melliez D Levybruhl PY Boelle B Dervaux S Baron Y Yazdanpanah, Vaccine 2008 26 5 706 15 10.1016/j.vaccine.2007.11.064 18166250
57. The cost-effectiveness of rotavirus vaccination in Australia. AT Newall P Beutels K Macartney J Wood CR MacIntyre, Vaccine 2007 25 52 8851 60 10.1016/j.vaccine.2007.10.009 18022735
58. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. E Shim AP Galvani, Vaccine 2009 27 30 4025 30 10.1016/j.vaccine. 2009.04.030 19389452
59. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. M Jit J Bilcke MJ Mangen H Salo H Melliez WJ Edmunds Y Yazdan P Beutels, Vaccine 2009 27 44 6121 8 10.1016/j.vaccine.2009.08.030 19715781
60. Health and economic outcomes of HPV 16,18 Vaccination in 72 GAVI-eligible countries. SJ Goldie M O'Shea NG Campos M Diaz S Sweet S Kim, Vaccine 2008 26 32 4080 93 10.1016/j.vaccine.2008.04.053 18550229
61. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. J Ferlay F Bray P Pisani DM Parkin, IARC Cancer Base No. 5 Version 2.0 Lyon, France: IARCPress 2004
62. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. C Jehu-Appiah R Baltussen C Acquah M Aikins SA d'Almeida WK Bosu X Koolman J Lauer D Osei S Adjei, Value in Health 2008 11 1081 87 10.1111/j.1524-4733.2008.00392.x 19602214
63. Priority setting of health interventions: the need for multi-criteria decision analysis. R Baltussen L Niessen, Cost Effectiveness and Resource Allocation 2006 4 14 16923181
64. Priority Setting using multiple criteria: should a lung health programme be implemented in Nepal? R Baltussen AHA Asbroek X Koolman N Shrestha P Bhattarai LW Niessen, Health Policy and Planning 2007 22 178 185 10.1093/heapol/czm010 17412742
65. Efficiency, Equity, and Budgetary Policies: Informing Decisions Using Mathematical Programming. DM Epstein Z Chalabi K Claxton M Sculpher, Medical Decision Making 2007 27 128 137 10.1177/0272989X06297396 17409363
66. Demographic Variability, Vaccination, and the Spatiotemporal Dynamics of Rotavirus Epidemics. VE Pitzer C Viboud L Simonsen C Steiner CA Panozzo WJ Alonso MA Miller RI Glass JW Glasser UD Parashar BT Grenfell, Science 2009 35 5938 290 294 10.1126/science.1172330
67. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. S Kim SJ Goldie, Pharmacoeconomics 2008 26 3 191 215 10.2165/00019053-200826030-00004 18282015
68. Defeating Rotavirus? The Global Recommendation for Rotavirus Vaccination. MH Danchin JE Bines, N Engl J Med 2009 361 20 1919 1921 10.1056/NEJMp0905091 19907040